Trevi Therapeutics (TRVI) Share-based Compensation (2018 - 2026)
Trevi Therapeutics' quarterly Share-based Compensation came in at $2.2 million in Q1 2026, up 81.37% year-on-year from $1.2 million in Q1 2025, and up 62.3% quarter-over-quarter from $1.3 million in Q4 2025.
Trevi Therapeutics has reported Share-based Compensation for 9 years, with the latest figure at $2.2 million in Q1 2026.
- For the quarter ending Q1 2026, Share-based Compensation rose 81.37% year-over-year to $2.2 million; the trailing twelve-month figure through Mar 2026 stood at $6.2 million (up 51.4% YoY), and the FY2025 full-year result was $5.2 million, up 44.51% from the prior year.
- Share-based Compensation for Q1 2026 stood at $2.2 million, up from $1.3 million in the prior quarter.
- The five-year high for Share-based Compensation was $2.2 million in Q1 2026, with the low at $501000.0 in Q4 2022.
- Average Share-based Compensation over 5 years is $909647.1, with a median of $737000.0 recorded in 2022.
- Year-over-year, Share-based Compensation tumbled 30.2% in 2022 and surged 112.64% in 2024.
- Tracing TRVI's Share-based Compensation over 5 years: stood at $501000.0 in 2022, then rose by 6.59% to $534000.0 in 2023, then surged by 71.72% to $917000.0 in 2024, then soared by 47.22% to $1.3 million in 2025, then jumped by 62.3% to $2.2 million in 2026.
- The last three Share-based Compensation figures came in at $2.2 million (Q1 2026), $1.3 million (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 892,057.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 305,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 166.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 257.40 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.15 Mn |
| 10 | Trevi Therapeutics | 2.02 Bn | 1.85 Bn | - | 2.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.19 Mn |
| Mar 31, 2026 | 2.19 Mn |
| Dec 31, 2025 | 1.35 Mn |
| Dec 31, 2025 | 1.35 Mn |
| Sep 30, 2025 | 1.24 Mn |
| Sep 30, 2025 | 1.24 Mn |
| Jun 30, 2025 | 1.38 Mn |
| Jun 30, 2025 | 1.38 Mn |
| Mar 31, 2025 | 1.21 Mn |
| Mar 31, 2025 | 1.21 Mn |
| Dec 31, 2024 | 917,000.00 |
| Dec 31, 2024 | 917,000.00 |
| Sep 30, 2024 | 822,000.00 |
| Sep 30, 2024 | 822,000.00 |
| Jun 30, 2024 | 1.13 Mn |
| Jun 30, 2024 | 1.13 Mn |
| Mar 31, 2024 | 723,000.00 |
| Mar 31, 2024 | 723,000.00 |
| Dec 31, 2023 | 534,000.00 |
| Dec 31, 2023 | 534,000.00 |
| Sep 30, 2023 | 530,000.00 |
| Sep 30, 2023 | 530,000.00 |
| Jun 30, 2023 | 530,000.00 |
| Jun 30, 2023 | 530,000.00 |
| Mar 31, 2023 | 578,000.00 |
| Mar 31, 2023 | 578,000.00 |
| Dec 31, 2022 | 501,000.00 |
| Dec 31, 2022 | 501,000.00 |
| Sep 30, 2022 | 569,000.00 |
| Sep 30, 2022 | 569,000.00 |
| Jun 30, 2022 | 520,000.00 |
| Jun 30, 2022 | 520,000.00 |
| Mar 31, 2022 | 737,000.00 |
| Mar 31, 2022 | 737,000.00 |
| Dec 31, 2021 | 540,000.00 |
| Dec 31, 2021 | 540,000.00 |
| Sep 30, 2021 | 540,000.00 |
| Sep 30, 2021 | 540,000.00 |
| Jun 30, 2021 | 745,000.00 |
| Jun 30, 2021 | 745,000.00 |
| Mar 31, 2021 | 718,000.00 |
| Mar 31, 2021 | 718,000.00 |
| Dec 31, 2020 | 510,000.00 |
| Dec 31, 2020 | 510,000.00 |
| Sep 30, 2020 | 588,000.00 |
| Sep 30, 2020 | 588,000.00 |
| Jun 30, 2020 | 589,000.00 |
| Jun 30, 2020 | 589,000.00 |
| Mar 31, 2020 | 730,000.00 |
| Mar 31, 2020 | 730,000.00 |
| Dec 31, 2019 | 373,000.00 |
| Dec 31, 2019 | 373,000.00 |
| Sep 30, 2019 | 371,000.00 |
| Sep 30, 2019 | 371,000.00 |
| Jun 30, 2019 | 237,000.00 |
| Jun 30, 2019 | 237,000.00 |
| Mar 31, 2019 | 146,000.00 |
| Mar 31, 2019 | 146,000.00 |
| Dec 31, 2018 | 185,000.00 |
| Dec 31, 2018 | 185,000.00 |
| Sep 30, 2018 | 121,000.00 |
| Sep 30, 2018 | 121,000.00 |
| Jun 30, 2018 | 102,000.00 |
| Jun 30, 2018 | 102,000.00 |
| Mar 31, 2018 | 88,000.00 |
| Mar 31, 2018 | 88,000.00 |